TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,576,000 | +156.5% | 400,000 | +340.8% | 0.12% | +197.5% |
Q2 2023 | $1,393,889 | -31.7% | 90,748 | 0.0% | 0.04% | -33.3% |
Q1 2023 | $2,040,923 | +6.9% | 90,748 | 0.0% | 0.06% | +11.1% |
Q4 2022 | $1,908,430 | -14.6% | 90,748 | 0.0% | 0.05% | -16.9% |
Q3 2022 | $2,236,000 | -83.8% | 90,748 | -84.1% | 0.06% | -85.0% |
Q2 2022 | $13,813,000 | -71.0% | 570,084 | -69.1% | 0.43% | -54.6% |
Q1 2022 | $47,560,000 | -58.5% | 1,845,555 | -50.0% | 0.95% | +7.8% |
Q4 2021 | $114,572,000 | +140.4% | 3,691,110 | +87.8% | 0.88% | +27.7% |
Q3 2021 | $47,665,000 | -11.5% | 1,965,555 | -46.7% | 0.69% | +97.7% |
Q2 2021 | $53,854,000 | -34.6% | 3,691,110 | +11.9% | 0.35% | -66.4% |
Q1 2021 | $82,362,000 | -13.5% | 3,298,419 | -5.6% | 1.04% | +2.0% |
Q4 2020 | $95,218,000 | – | 3,493,607 | – | 1.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |